2016
DOI: 10.1016/j.bone.2016.02.014
|View full text |Cite
|
Sign up to set email alerts
|

Effects of 16-month treatment with the cathepsin K inhibitor ONO-5334 on bone markers, mineral density, strength and histomorphometry in ovariectomized cynomolgus monkeys

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
9
0

Year Published

2016
2016
2020
2020

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 10 publications
(9 citation statements)
references
References 35 publications
0
9
0
Order By: Relevance
“…The three-dimensional (3D) images were rebuilt by the software (CTVol, Skyscan). There were 50 consecutive slices (1.5 mm) selected as the region of interest beginning 6.22 mm away from the distal femur growth plate to analyze the trabecular bone (Yamada et al, 2016). For the quantitative analysis, the following measurements were obtained by the software: bone volume/tissue volume (BV/TV), bone surface/bone volume (BS/BV), trabecular thickness (Tb.Th), trabecular number (Tb.N), mean trabecular spacing (Tb.Sp), and bone mineral density (BMD).…”
Section: Methodsmentioning
confidence: 99%
“…The three-dimensional (3D) images were rebuilt by the software (CTVol, Skyscan). There were 50 consecutive slices (1.5 mm) selected as the region of interest beginning 6.22 mm away from the distal femur growth plate to analyze the trabecular bone (Yamada et al, 2016). For the quantitative analysis, the following measurements were obtained by the software: bone volume/tissue volume (BV/TV), bone surface/bone volume (BS/BV), trabecular thickness (Tb.Th), trabecular number (Tb.N), mean trabecular spacing (Tb.Sp), and bone mineral density (BMD).…”
Section: Methodsmentioning
confidence: 99%
“…We think the reason why there was no significant difference was that the sample size was small and the analysis period was short. ONO-5334 has shown potent selective inhibition of cathepsin K in vitro and has resulted in improvement in both BMD and bone strength in osteoporosis models ( Ochi et al, 2014 ; Eastell et al, 2014 ; Engelke et al, 2014 ; Yamada et al, 2016 ). In the first clinical study of ONO-5334, Eastell et al (2011) investigated the efficacy and safety of the compound in postmenopausal women with osteoporosis.…”
Section: Discussionmentioning
confidence: 99%
“…Animals received test articles for 9 weeks from the day of the first sensitization. The dose level of ONO-5334 was decided based on the results from an OVX monkey osteoporosis study [18]. ONO-5334 at 30 mg/kg prevented OVX-induced decreases in bone mass and strength.…”
Section: Methodsmentioning
confidence: 99%
“…ONO-5334 is a low molecular weight synthetic inhibitor of cathepsin K with Ki value of 0.1 nM [17]. In previous studies, we have shown that ONO-5334 suppresses bone resorption and increases bone mineral density in ovariectomized (OVX) cynomolgus monkeys [18, 19] and in patients with postmenopausal osteoporosis [20, 21]. The monkey CIA model may be more suitable for prediction of clinical efficacy in RA than rodent CIA models because monkeys are phylogenetically and physiologically close to human beings [22, 23].…”
Section: Introductionmentioning
confidence: 99%